Kymera Therapeutics, Inc.
KYMR
$25.97
$0.953.80%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -223.86M | -167.47M | -157.85M | -154.59M | -146.96M |
| Total Depreciation and Amortization | 7.37M | 6.28M | 5.19M | 4.15M | 3.57M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 45.95M | 45.05M | 44.21M | 43.65M | 37.89M |
| Change in Net Operating Assets | -23.97M | -8.53M | 2.33M | 8.34M | 2.68M |
| Cash from Operations | -194.50M | -124.67M | -106.13M | -98.45M | -102.83M |
| Capital Expenditure | -12.84M | -23.53M | -31.79M | -37.87M | -34.48M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -391.24M | -430.17M | -203.71M | -177.43M | 174.37M |
| Cash from Investing | -404.08M | -453.69M | -235.50M | -215.31M | 139.89M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.58M | -358.00K | -57.00K | -39.00K | -76.00K |
| Issuance of Common Stock | 638.79M | 608.38M | 356.95M | 356.83M | 4.27M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -28.36M | -- | -- | -- | -- |
| Cash from Financing | 608.85M | 608.02M | 356.90M | 356.79M | 4.19M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.27M | 29.66M | 15.27M | 43.04M | 41.25M |